HealthEquity (HQY)
(Delayed Data from NSDQ)
$79.56 USD
+2.47 (3.20%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $79.51 -0.05 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.56 USD
+2.47 (3.20%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $79.51 -0.05 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Zacks News
Here's Why You Should Add DexCom (DXCM) to Your Portfolio
by Zacks Equity Research
DexCom (DXCM) raises its 2019 revenue and EPS guidance.
LHC Group Expands Partnership With Tennessee-Based Medalogix
by Zacks Equity Research
Management at LHC Group (LHCG) expects to complete the expansion by the first quarter of 2020.
Will HealthEquity Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor HealthEquity.
3 Stocks to Consider as Retail Spending Slows
by Christopher Vargas
The stock market saw tepid movement Friday after the US struck a phase one deal with China.
McKesson, Walgreens Form JV for European Pharmaceutical Unit
by Zacks Equity Research
The VA selects McKesson (MCK) as their prime pharmaceutical supplier.
LHC Group Set to Gain From Expansion of LifePoint Health JV
by Zacks Equity Research
LHC Group (LHCG) expects approximately $5.4 million in annualized revenues from this transaction.
ERFSF vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ERFSF vs. HQY: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to Ecolab (ECL) Stock for Now
by Zacks Equity Research
Ecolab (ECL) slashes 2019 EPS view owing to foreign exchange headwinds.
Company News for Dec 5, 2019
by Zacks Equity Research
Companies In The News Are: HQY, CRM, CPB, RY
Here's Why You Should Hold on to HealthEquity (HQY) for Now
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q3
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
HealthEquity (HQY) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 113.64% and 3.29%, respectively, for the quarter ended October 2019. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) Up 73% Year to Date: Will the Rally Continue?
by Sapna Bagaria
Teladoc's (TDOC) presence in the growing telehealth industry with many deal wins and international expansion is likely to drive long-term growth.
ERFSF vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ERFSF vs. HQY: Which Stock Is the Better Value Option?
ERFSF vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ERFSF vs. HQY: Which Stock Is the Better Value Option?
ERFSF or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ERFSF vs. HQY: Which Stock Is the Better Value Option?
HealthEquity (HQY) Down 5.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ERFSF vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ERFSF vs. HQY: Which Stock Is the Better Value Option?
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
HealthEquity (HQY) gains from solid segmental contributions in second-quarter fiscal 2020.
HealthEquity Acquires WageWorks, To Make Notable Investments
by Zacks Equity Research
HealthEquity (HQY) expects to complete its $80-100 million investment program within 24-36 months from now.
What's in the Cards for HealthEquity (HQY) in Q2 Earnings?
by Zacks Equity Research
Higher revenues and possible margin expansion are likely to aid HealthEquity (HQY) in Q2 earnings.
HealthEquity (HQY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HealthEquity (HQY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
HealthEquity (HQY) closed at $58.62 in the latest trading session, marking a +0.15% move from the prior day.
HealthEquity (HQY) Stock Moves -0.51%: What You Should Know
by Zacks Equity Research
In the latest trading session, HealthEquity (HQY) closed at $60.69, marking a -0.51% move from the previous day.
HealthEquity (HQY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
HealthEquity (HQY) closed at $68.50 in the latest trading session, marking a +1.41% move from the prior day.